Literature DB >> 22508626

A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model.

David Hu1, Ontario D Lau, Linda Wang, Guanyu Wang, Dorthe Schaue, Li Zhu, Min Huang, Yuan Lin, Miranda Dennis, Elliot Abemayor, David A Elashoff, Steven M Dubinett, William H McBride, Sherven Sharma, Ben Wu, Maie A St John.   

Abstract

OBJECTIVE: To evaluate the therapeutic efficacy of a novel modular polymer platform in the treatment of head and neck squamous cell carcinoma (HNSCC).
DESIGN: In vivo study.
SETTING: Academic research laboratory. Subjects and
METHODS: C3H/HeJ mice and SCID/beige mice were randomized to receive implantation of no polymer, plain polymer, plain polymer with local cisplatin injection, or cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive 4 Gy of external beam radiation for 4 days or no radiation. Tumor size was measured until the mice were humanely killed. At necropsy, the tumors were excised and weighed.
RESULTS: There was a significant reduction in tumor growth using this novel polymer platform. The cisplatin-secreting polymer effectively reduced human head and neck tumor growth in SCID mice by 17-fold and SCC VII/SF tumors in C3H/HeJ mice by more than 16-fold compared with the control, plain polymer, and plain polymer + intratumoral cisplatin injection groups (P = .01 for both). We also observed a statistically significant lower tumor weight in mice treated with cisplatin polymer and concomitant radiation compared with the radiation alone and control groups.
CONCLUSIONS: We demonstrate the efficacy of a novel polymer platform in delivering cisplatin to a partially resected SCC in a murine model. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan for validation in the context of a prospective trial in patients with unresectable advanced or recurrent HNSCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508626      PMCID: PMC4167672          DOI: 10.1001/archoto.2012.20

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  16 in total

Review 1.  Mechanisms of polymer degradation and erosion.

Authors:  A Göpferich
Journal:  Biomaterials       Date:  1996-01       Impact factor: 12.479

2.  Response of murine tumors to matrix-associated cisplatin intratumoral implants.

Authors:  N Y Yu; F K Conley; E E Luck; D M Brown
Journal:  NCI Monogr       Date:  1988

3.  Efficacy of a spray compound containing a pool of collagen precursor synthetic aminoacids (l-proline, l-leucine, l-lysine and glycine) combined with sodium hyaluronate to manage chemo/radiotherapy-induced oral mucositis: preliminary data of an open trial.

Authors:  G Colella; R Cannavale; A Vicidomini; G Rinaldi; D Compilato; G Campisi
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Jan-Mar       Impact factor: 3.219

4.  Polymer chemotherapy for head and neck cancer.

Authors:  A H Shikani; A J Domb
Journal:  Laryngoscope       Date:  2000-06       Impact factor: 3.325

5.  A new immunocompetent murine model for oral cancer.

Authors:  B W O'Malley; K A Cope; C S Johnson; M R Schwartz
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1997-01

Review 6.  Altered fractionation schemes in radiotherapy.

Authors:  Martin Stuschke; Christoph Pöttgen
Journal:  Front Radiat Ther Oncol       Date:  2009-11-24

7.  Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice.

Authors:  D T Yapp; D K Lloyd; J Zhu; S M Lehnert
Journal:  Anticancer Drugs       Date:  1998-10       Impact factor: 2.248

8.  Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy.

Authors:  Douglas A Ross; Jagdeep S Hundal; Yung H Son; Stephan Ariyan; Joseph Shin; Roger Lowlicht; Clarence T Sasaki
Journal:  Laryngoscope       Date:  2004-07       Impact factor: 3.325

9.  Permanent iodine-125 implants in postoperative radiotherapy for head and neck cancer with positive surgical margins.

Authors:  B Vikram; S Mishra
Journal:  Head Neck       Date:  1994 Mar-Apr       Impact factor: 3.147

10.  Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.

Authors:  M J Deurloo; W Kop; O van Tellingen; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more
  5 in total

1.  Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.

Authors:  Brittany J Poelaert; Svetlana Romanova; Shelby M Knoche; Madeline T Olson; Bailee H Sliker; Kaitlin Smits; Brittney L Dickey; Alexandra E J Moffitt-Holida; Benjamin T Goetz; Nuzhat Khan; Lynette Smith; Hamid Band; Aaron M Mohs; Donald W Coulter; Tatiana K Bronich; Joyce C Solheim
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

2.  Novel Pactamycin Analogs Induce p53 Dependent Cell-Cycle Arrest at S-Phase in Human Head and Neck Squamous Cell Carcinoma (HNSCC) Cells.

Authors:  Gunjan Guha; Wanli Lu; Shan Li; Xiaobo Liang; Molly F Kulesz-Martin; Taifo Mahmud; Arup Kumar Indra; Gitali Ganguli-Indra
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

3.  Validation of a Three-Dimensional Head and Neck Spheroid Model to Evaluate Cameras for NIR Fluorescence-Guided Cancer Surgery.

Authors:  Claire Egloff-Juras; Ilya Yakavets; Victoria Scherrer; Aurélie Francois; Lina Bezdetnaya; Henri-Pierre Lassalle; Gilles Dolivet
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

4.  A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer.

Authors:  Manijeh Goldberg; Aaron Manzi; Peter Conway; Stefanie Cantin; Vasudha Mishra; Alka Singh; Alexander T Pearson; Eric R Goldberg; Sam Goldberger; Benjamin Flaum; Rifat Hasina; Nyall R London; Gary L Gallia; Chetan Bettegowda; Sonya E O'Neill; Erkin Aydin; Alex Zhavoronkov; Anxo Vidal; Atenea Soto; Maria Jose Alonso; Ari J Rosenberg; Mark W Lingen; Anil D'Cruz; Nishant Agrawal; Evgeny Izumchenko
Journal:  Nat Commun       Date:  2022-08-17       Impact factor: 17.694

5.  CCL21 Cancer Immunotherapy.

Authors:  Yuan Lin; Sherven Sharma; Maie St John
Journal:  Cancers (Basel)       Date:  2014-05-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.